KRAS and neoplasm: Moreover, 26.1% of analyzed tumors presented missense mutations in KRAS (6/22) and 13% in PIK3CA. Finally, only one tumor presented a missense mutation in FBXW7 and a stop mutation in SMAD4 and one had a missense mutation in EGFR (Figure 7D,E).